Einrichtungen Einrichtung-Details

Institut für Biometrie und Registerforschung

Die Aufgaben des Instituts umfassen den Aufbau und die Leitung des Klinischen Studienzentrums der MHB und die Unterstützung des zentralen Bereichs Versorgungsforschung insbesondere auf dem Gebiet der Registerforschung.

Zudem hat das Institut eine wichtige Rolle bei der Lehre an der MHB, u.a. bei Methoden wissenschaftlichen Arbeitens, im Modul Biometrie und in der statistischen Betreuung der Studierenden während des Wissenschaftspraktikums und für Promotionsprojekte.

Wissenschaftliche Schwerpunkte

Die Forschung des Instituts für Biometrie und Registerforschung richtet sich auf die Anwendung und Entwicklung innovativer statistischer Methoden und Studiendesigns. Im Rahmen der Zusammenarbeit innerhalb klinischer Studien bringt das Institut Expertise ein in Design, Auswertung und Interpretation der Ergebnisse. Das Ziel ist, aus medizinischen Daten einen möglichst hohen und validen Informationsgewinn zu ziehen. Im Rahmen der Registerforschung werden mit Daten aus öffentlichen Registern klinische Interventionen getestet, um so eine evidenzbasierte Behandlung zu liefern und/oder zu verbessern.

Ausgewählte Publikationen

Teepen JC, Kok JL, Kremer LC, Tissing WJ, Van den Heuvel-Eibrink MM, Loonen JJ, Bresters D, Van der Pal HJ, Versluys B, Van Dulmen-den Broeder E, Nijsten T, Hauptmann M, Hollema N, Dolsma WV, Van Leeuwen FE, Ronckers CM, DCOG-LATER Study Group. Long-term risk of skin cancer among childhood cancer survivors: a DCOG-LATER cohort study. J Natl Cancer Inst. In press.

Teepen JC, Kok JL, Kremer LC, Tissing WJE, Van den Heuvel-Eibrink MM, Loonen JJ, Bresters D, Van der Pal HJ, Versluys B, Van Dulmen-den Broeder E, Nijsten T, Hauptmann M, Hollema N, Dolsma WV, Van Leeuwen FE, Ronckers CM; DCOG-LATER Study Group. Long-term risk of skin cancer among childhood cancer survivors: A DCOG-LATER Cohort Study. J Natl Cancer Inst. In press.

Van der Willik KD, Hauptmann M, Jóźwiak K, Vinke EJ, Ruiter R, Stricker BH, Compter A, Ikram A, Schagen SB. Trajectories of cognitive performance prior to cancer diagnosis: a population-based study. J Natl Cancer Inst. In press.

Constine LS, Ronckers CM, Hua CH, Olch A, Kremer LCM, Jackson A, Bentzen SM. Pediatric normal tissue effects in the clinic (PENTEC): An international collaboration to analyse normal tissue radiation dose-volume response relationships for paediatric cancer patients. Clin Oncol (R Coll Radiol) 2019; 31: 199–207.

Kok JL, Teepen JC, Van Leeuwen FE, Tissing WJE, Neggers SJCMM, Van der Pal HJ, Loonen JJ, Bresters D, Versluys B, Van den Heuvel-Eibrink MM, Van Dulmen-den Broeder E, Van der Heiden-van der Loo M, Aleman BMP, Daniels LA, Haasbeek CJA, Hoeben B, Janssens GO, Maduro JH, Oldenburger F, Van Rij C, Tersteeg RJHA, Hauptmann M; DCOG-LATER Study Group, Kremer LCM, Ronckers CM. Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age. Neuro Oncol 2019; 21(3): 392–403.

Meulepas JM, Ronckers CM, Smets AM, Nievelstein RA, Gradowska P, Lee C, Jahnen A, Van Straten M, De Wit MC, Zonnenberg B, Klein WM, Merks JH, Visser O, Van Leeuwen FE, Hauptmann M. Radiation exposure from pediatric CT scans and subsequent cancer risk in the Netherlands. J Natl Cancer Inst 2019; 111(3): 256–263.

Opstal-Van Winden AW, De Haan HG, Hauptmann M, Schmidt MK, Broeks A, Russell NS, Janus CP, Krol AD, Van der Baan FH, De Bruin ML, Van Eggermond AM, Dennis J, Culver HA, Haiman CA, Sawyer EJ, Cox A, Devilee P, Hooning MJ, Peto J, Couch FJ, Pharoah P, Orr P, Easton DF, Aleman BM, Strong LC, Bhatia S, Cooke R, Robison LL, Swerdlow AJ, Van Leeuwen FE. Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma. Blood 2019; 133(10): 1130–1139.

Puppe J, Opdam M, Schouten PC, Jóźwiak K, Lips E, Severson T, Van de Ven M, Brambillasca C, Bouwman P, van Tellingen O, Bernards R, Wesseling J, Eichler C, Thangarajah F, Malter W, Pandey GK, Ozretić L, Caldas C, van Lohuizen M, Hauptmann M, Rhiem K, Hahnen E, Reinhardt HC, Büttner R, Mallmann P, Schömig-Markiefka B, Schmutzler R, Linn S, Jonkers J. EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy. Clin Cancer Res 2019; 25(14): 4351–4362.

Teepen JC, Ronckers CM, Kremer LCM. Colorectal cancer screening in childhood cancer survivors (editorial). J Natl Cancer Inst 2019, 111(11): djz063.

Bright CJ, Hawkins MM, Winter DL, Alessi D, Allodji RS, Bagnasco F, Bárdi E, Bautz A, Byrne J, Feijen EAM, Fidler MM, Garwicz S, Grabow D, Gudmundsdottir T, Guha J, Haddy N, Jankovic M, Kaatsch P, Kaiser M, Kuehni CE, Linge H, Øfstaas H, Ronckers CM, Skinner R, Teepen JC, Terenziani M, Vu-Bezin G, Wesenberg F, Wiebe T, Sacerdote C, Jakab Z, Haupt R, Lähteenmäki P, Zaletel LZ, Kuonen R, Winther JF, de Vathaire F, Kremer LC, Hjorth L, Reulen RC; PanCareSurFup Consortium. Risk of soft-tissue sarcoma among 69, 460 5-year survivors of childhood cancer in Europe. J Natl Cancer Inst 2018; 110(6): 649–660.

De Boer M, Van Leeuwen FE, Hauptmann M, Overbeek LI, De Boer JP, Hijmering NJ, Sernee A, Klazen CA, Lobbes MB, Van der Hulst RR, Rakhorst HA, De Jong D. Breast implants and the risk of anaplastic large cell lymphoma in the breast. JAMA Oncol 2018; 4(3): 335–341.

Groot HJ, Lubberts S, De Wit R, Witjes JA, Kerst JM, De Jong IJ, Groenewegen G, Van den Eertwegh AJM, Poortmans PM, Klumpen H, Van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJB, Incrocci L, Van den Bergh ACM, Jóźwiak K, Van den Belt-Dusebout AW, Horenblas S, Gietema JA, Van Leeuwen FE, Schaapveld M. Risk of solid cancer after treatment for testicular germ cell cancer in the platinum era. J Clin Oncol 2018; 36(4): 2504–2513.

Krul IMK, Opstal-Van Winden AWJ, Janus CPM, Daniels LA, Appelman Y, Maas AHEM, De Vries S, Jóźwiak K, Aleman BMP, Van Leeuwen F. Cardiovascular disease risk after treatment-induced premature ovarian insuffciency in female survivors of Hodgkin lymphoma. J Am Coll Cardiol 2018; 72(25): 3374–3375.

Meulepas JM, Hauptmann M, Lubin JH, Shuryak I, Brenner DJ. Is there unmeasured indication bias in radiation-related cancer risk estimates from studies of computed tomography? Radiat Res 2018; 189(2): 128–135.

Teepen JC, Kok JL, Van Leeuwen FE, Tissing WJE, Dolsma WV, Van der Pal HJ, Loonen JJ, Bresters D, Versluys B, Van den Heuvel-Eibrink MM, Van Dulmen-den Broeder E, Van den Berg MH, Van der Heiden-van der Loo M, Hauptmann M, Jongmans MC, Overbeek LI, Van de Vijver MJ, Kremer LCM, Ronckers CM; DCOG-LATER Study Group. Colorectal adenomas and cancers after childhood cancer treatment: A DCOG-LATER Record Linkage Study. J Natl Cancer Inst 2018; 110(7): 758–767.

Turcotte LM, Neglia JP, Reulen RC, Ronckers CM, Van Leeuwen FE, Morton LM, Oeffinger KC, Henderson TO.  Risk factors and surveillance of subsequent malignant neoplasms in childhood cancer survivors: A Review. J Clin Oncol 2018; 36: 2145–2152.

Meulepas JM, Smets AMJB, Nievelstein RAJ, Gradowska P, Verbeke J, Holscher HC, Rutten MJCM, Kieft M, Ronckers CM, Hauptmann M. Trends and patterns of computed tomography scan use among children in the Netherlands: 1990-2012. Eur Radiol 2017; 27(6): 2426–2433.

Teepen JC, Van Leeuwen FE, Tissing WJ, Van Dulmen-den Broeder E, Van den Heuvel-Eibrink MM, Van der Pal HJ, Loonen JJ, Bresters D, Versluys B, Neggers SJCMM, Jaspers MWM, Hauptmann M, Van der Heiden-van der Loo M, Visser O, Kremer LCM, Ronckers CM; DCOG LATER Study Group. Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER Study Cohort:  Role of chemotherapy. J Clin Oncol 2017; 35(20): 2288–2298.

Van Nimwegen FA, Ntentas G, Darby SC, Schaapveld M, Hauptmann M, Lugtenburg PJ, Janus CPM, Daniels L, Van Leeuwen FE, Cutter DJ, Aleman BMP. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood 2017; 129(16): 2257–2265.

Hauptmann M, Johannesen TB, Gilbert ES, Stovall M, Van Leeuwen FE, Rajaraman P, Smith SA, Weathers RE, Aleman BM, Andersson M, Curtis RE, Dores GM, Fraumeni Jr JF, Hall P, Holowaty EJ, Joensuu H, Kaijser M, Kleinerman RA, Langmark F, Lynch CF, Pukkala E, Storm HH, Vaalavirta L, Van den Belt-Dusebout AW, Morton LM, Fossa SD, Travis LB. Increased pancreatic cancer risk following radiotherapy for testicular cancer. Br J Cancer 2016; 115: 901–908.

Meulepas JM, Ronckers CM, Merks J, Weijerman ME, Lubin JH, Hauptmann M. Confounding of the association between radiation exposure from CT scans and risk of leukemia and brain tumors by cancer susceptibility syndromes. J Radiol Prot 2016; 36(4): 953–974.

Teepen JC, De Vroom SL, Van Leeuwen FE, Tissing W, Kremer LCM, Ronckers CM. Risk of subsequent gastrointestinal tract cancer among childhood cancer survivors: A systematic review. Cancer Treat Rev 2016; 43: 92-103.

Van den Belt-Dusebout AW, Spaan M, Lambalk CB, Kortman M, Laven JS, Van Santbrink EJ, Van der Westerlaken LA, Cohlen BJ, Braat DD, Smeenk JM, Land JA, Goddijn M, Van Golde RJ, Van Rumste MM, Schats R, Jóźwiak K, Hauptmann M, Rookus MA, Burger CW, Van Leeuwen FE. Association between ovarian stimulation for in vitro fertilization and long-term risk of breast cancer. JAMA 2016; 316(3): 300–312

Van Leeuwen FE. Ronckers CM. Anthracyclines and alkylating agents: new risk factors for breast cancer in childhood cancer survivors? (Editorial). J Clin Oncol 2016; 34: 891-894.

Van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CP, Krol AD, Hauptmann M, Kooijman K, Roesink J, Van der Maazen R, Darby SC, Aleman BM, Van Leeuwen FE. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 2016; 34(3): 235–243.

Cutter D, Schaapveld M, Darby SC, Hauptmann M, Van Nimwegen FA, Krol SA, Janus C, Van Leeuwen FE, Aleman BM. Risk of valvular heart disease after radiotherapy for Hodgkin lymphoma. J Natl Cancer Inst 2015; 107(4).

Hauptmann M, Fossa SD, Stovall M, Van Leeuwen FE, Johannesen TB, Rajaraman P, Gilbert ES, Smith SA, Weathers RE, Aleman BM, Andersson M, Curtis RE, Dores GM, Fraumeni Jr JF, Hall P, Holowaty EJ, Joensuu H, Kaijser M, Kleinerman RA, Langmark F, Lynch CF, Pukkala E, Storm HH, Vaalavirta L, Van den Belt-Dusebout AW, Travis LB, Morton LM. Increased stomach cancer risk following radiotherapy for testicular cancer. Br J Cancer 2015; 112(1): 44–51.

Schouten PC, Marme F, Aulmann S, Sinn HP, Van Essen HJ, Ylstra B, Hauptmann M, Schneeweiss A, Linn SC. Breast cancers with a BRCA1-like DNA copy number profile recur less often than expected after high-dose alkylating chemotherapy. Clin Cancer Res 2015; 21(4): 763–770.

Theunissen EA, Zuur CL, Jóźwiak K, Lopez-Yurda M, Hauptmann M, Rasch CR, Van der Baan S, De Boer JP, Dreschler WA, Balm AJ. Prediction of hearing loss due to cisplatin chemoradiotherapy. JAMA Otolaryngol Head Neck Surg 2015; 141(9): 810–815.

 

 


Leitung:


Teammitglieder: